Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

NCT05001945
View directory record Official record
Conditions
Hypertension, Renal
Interventions
MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II)
Drug · Other
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
44
States / cities
Lincoln, California • Torrance, California • Tustin, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 23, 2026, 6:03 PM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional

Chyme Reinfusion for Type 2 Intestinal Failure

NCT04577456
View directory record Official record
Conditions
Intestinal Failure, Enterocutaneous Fistula, Ileostomy - Stoma, High Output Stoma
Interventions
The Insides System
Device
Lead sponsor
The Insides Company
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 23, 2026, 6:03 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

NCT00473824
View directory record Official record
Conditions
Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
Interventions
Hepatitis C Immune Globulin Intravenous (Human) 5%
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 23, 2026, 6:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)

NCT01766180
View directory record Official record
Conditions
Memory Impairment
Interventions
Fruitflow-II, resVida
Drug
Lead sponsor
Neurolgy Institute for Brain Health and Fitness
Other
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 23, 2026, 6:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT01648322
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
F-627, Neulasta® (pegfilgrastim)
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 74 Years · Female only
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Anderson, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 23, 2026, 6:03 PM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Don't Throw Your Heart Away: Medical Student Study 2

NCT04176796
View directory record Official record
Conditions
Cardiac Transplant Disorder
Interventions
Stratified Transplant Survival
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder

NCT01126827
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

NCT00950248
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Idebenone, placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 23, 2026, 6:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Couples-Based Yoga Program in Improving Quality of Life in Patients With High-Grade Glioma Undergoing Radiation Therapy and Their Partners

NCT02481349
View directory record Official record
Conditions
Caregiver, Glioma
Interventions
Best Practice, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

NCT02496585
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Nintedanib, Prednisone, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 23, 2026, 6:03 PM EDT
Not yet recruiting Early Phase 1 Interventional

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

NCT07757555
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions
Guanfacine (GFC), Cromolyn Sodium, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

NCT02972255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7079901, Meropenem, RO7049389 Placebo, Meropenem Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional

Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer

NCT02518308
View directory record Official record
Conditions
Anxiety, Cancer Survivor, Cognitive Impairment, Depression, Distress, Fatigue, Malignant Female Reproductive System Neoplasm, Pain, Sexual Dysfunction
Interventions
Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 23, 2026, 6:03 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

NCT07282743
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

NCT04030598
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis

NCT00004316
View directory record Official record
Conditions
Interstitial Cystitis, Vulvar Diseases
Interventions
capsaicin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

NCT00063414
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Alicaforsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 23, 2026, 6:03 PM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 23, 2026, 6:03 PM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 23, 2026, 6:03 PM EDT